Dynamic contrast-enhanced MRI evaluates the early response of human head and neck tumor xenografts following anti-EMMPRIN therapy with cisplatin or irradiation.

Academic Article

Abstract

  • PURPOSE: To assess the early therapeutic effects of anti-EMMPRIN (extracellular matrix metalloprotease inducer) antibody with/without cisplatin or X-ray radiation in head and neck cancer mouse models using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). MATERIALS AND METHODS: Mice bearing SCC1 (or OSC19) tumor xenografts were treated with anti-EMMPRIN antibody, radiation, cisplatin, or anti-EMMPRIN antibody plus cisplatin (or radiation) for a week (n = 4-5 per group). DCE-MRI was carried out on a 9.4T small animal MR scanner on days 0, 3, and 7, and K(trans) values were averaged in a 0.5-mm-thick peripheral tumor region. Ki67 and CD31 staining were implemented for all tumors after imaging. RESULTS: The K(trans) changes of SCC1 and OSC19 tumors treated with anti-EMMPRIN antibody for 3 days were -18 ± 8% and 4 ± 7%, respectively, which were significantly lower than those of control groups (39 ± 5% and 45 ± 7%; P = 0.0025 and 0.0220, respectively). When cisplatin was added, those were -42 ± 9% and -44 ± 9%, respectively, and with radiation, -45 ± 9% and -27 ± 10%, respectively, which were also significantly lower than those of control groups (P < 0.0001 for all four comparisons). In the eight groups untreated (served as control) or treated with anti-EMMPRIN antibody with/without cisplatin or radiation, the mean K(trans) change for 3 days was significantly correlated with the mean tumor volume change for 7 days (r = 0.74, P = 0.0346), Ki67-expressing cell density (r = 0.96, P = 0.0001), and CD31 density (r = 0.84, P = 0.0084). CONCLUSION: DCE-MRI might be utilized to assess the early therapeutic effects of anti-EMMPRIN antibody with/without chemotherapy or radiotherapy in head and neck cancer.
  • Published In

    Keywords

  • DCE-MRI, anti-EMMPRIN antibody, cisplatin, head and neck cancer, radiotherapy, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Basigin, Cell Line, Tumor, Chemoradiotherapy, Cisplatin, Contrast Media, Drug Monitoring, Early Detection of Cancer, Female, Head and Neck Neoplasms, Humans, Magnetic Resonance Imaging, Mice, Mice, Nude, Prognosis, Reproducibility of Results, Sensitivity and Specificity, Treatment Outcome
  • Digital Object Identifier (doi)

    Author List

  • Kim H; Hartman YE; Zhai G; Chung TK; Korb ML; Beasley TM; Zhou T; Rosenthal EL
  • Start Page

  • 936
  • End Page

  • 945
  • Volume

  • 42
  • Issue

  • 4